¼¼°èÀÇ Per Encounter ÀÇ·á ½ÃÀå
Per Encounter Medical
»óǰÄÚµå : 1744817
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 392 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Per Encounter ÀÇ·á ½ÃÀåÀº 2030³â±îÁö 3,032¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1,307¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Per Encounter ÀÇ·á ½ÃÀåÀº 2024-2030³â¿¡ CAGR 15.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 3,032¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¼Ò¸ðǰÀº CAGR 13.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 916¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µð¹ÙÀ̽º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 17.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 356¾ï ´Þ·¯, Áß±¹Àº CAGR 19.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Per Encounter ÀÇ·á ½ÃÀåÀº 2024³â¿¡ 356¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 647¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 19.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 11.2%¿Í 13.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 11.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Per Encounter ÀÇ·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿À´Ã³¯ ÇコÄÉ¾î °æÁ¦¿¡¼­ Per Encounter ÀÇ·á ¸ðµ¨ÀÌ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ°¡ °³º° ȯÀÚÀÇ ¹æ¹® ¹× Ä¡·á À̺¥Æ®¿¡ µû¶ó º¸»óÀ» ¹Þ´Â Per Encounter ÀÇ·á ¸ðµ¨Àº ƯÈ÷ Fee-for-Service ȯ°æ¿¡¼­ Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °¡Ä¡ ±â¹Ý ÀÇ·á¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ¸¹Àº ¿Ü·¡Áø·á¼Ò, ÀÀ±Þ¼¾ÅÍ, Ä¡°ú, Áø´Ü°Ë»ç½Ç, Àü¹®ÀÇÀÇ Áø·á´Â ¿©ÀüÈ÷ Áø·á´ç û±¸ ü°è¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¸ðµ¨À» ÅëÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â 󸮷®, ÀÚ¿ø ¹èºÐ, Çö±Ý È帧À» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ ¸ðµ¨ÀÌ Åº·ÂÀûÀÎ ÀÌÀ¯ Áß Çϳª´Â ÁöºÒÀÚ °£ Á¶Á¤, ÀüÀڰǰ­±â·Ï(EHR)ÀÇ »óÈ£ ¿î¿ë¼º, °á°ú ÃßÀûÀÌ ¿©ÀüÈ÷ Á¦ÇÑÀûÀÎ ÆÄÆíÈ­µÈ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ Àû¿ë °¡´ÉÇÏ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ ¸ðµ¨Àº ÁßÀú¼Òµæ ±¹°¡¿Í ¼±Áø±¹ÀÇ ¹Î°£ ¹× ¹Ý¹Î°£ ÀÇ·á ºÎ¹®¿¡¼­ ƯÈ÷ ³Î¸® º¸±ÞµÇ¾î ÀÖÀ¸¸ç, ÀϰýÁöºÒ ¹× 1ÀÎ´ç ºÎ´ã±Ý Á¦µµ°¡ ¾ÆÁ÷ °³¹ß ´Ü°è¿¡ ÀÖ½À´Ï´Ù. °æ¹ÌÇÑ ½Ã¼ú, °Ë»ç, Áø´Ü µî ÀϽÃÀûÀÌ°í ±Þ¼ºÀÌ ³·Àº ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô´Â ´ë¸é »óȯÀÌ °æÁ¦ÀûÀ¸·Î ½ÇÇà °¡´ÉÇÏ°í °ü¸®ÀûÀ¸·Îµµ È¿À²ÀûÀÔ´Ï´Ù.

µðÁöÅÐ Çコ Ç÷§Æû, ȯÀÚ ¼±È£µµ, Åõ¸í¼º¿¡ ´ëÇÑ ¿ä±¸°¡ Áø·áºñ û±¸¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

µðÁöÅÐ ÀüȯÀº ´ë¸é Áø·á ¸ðµ¨ÀÇ ¿î¿µ ¹æ½ÄÀ» ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý Áø·á, ¿ø°Ý Áø´Ü °Ë»ç, ¸ð¹ÙÀÏ °Ç°­°ËÁøÀº ±âÁ¸ÀÇ ´ë¸é ±â¹Ý ÇÁ·¹ÀÓ¿öÅ©¿¡ »õ·Î¿î µðÁöÅÐ ·¹À̾ Ãß°¡Çϰí, ¼¼¼Ç ´ÜÀ§·Î û±¸µÇ´Â Ãß¼¼ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼­ºñ½º´Â ȯÀÚ¿¡°Ô´Â À¯¿¬¼º°ú Æí¸®ÇÔÀ» Á¦°øÇϰí, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô´Â ¿ÀÇÁ¶óÀÎ ¸ÅÀå ¿î¿µ¿¡ µû¸¥ ¿À¹öÇìµå ¾øÀ̵µ ´õ ³ÐÀº ½ÃÀåÀ¸·Î ÁøÃâÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¹æ¹®´ç ÁöºÒ ¹æ½ÄÀÇ ¿ø°ÝÀÇ·á ¼­ºñ½º°¡ º¸Çè ȯ±ÞÀÌ °¡´ÉÇÑ ½ÃÀå¿¡¼­´Â ÀÌ ¸ðµ¨ÀÌ ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª°ú Áö¹æÀÇ ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ȯÀÚµéÀº ƯÈ÷ ¼±ÅÃÀû ½Ã¼ú, ¿¹¹æÀû °ËÁø, ÀÚºñ ºÎ´ã ½Ã³ª¸®¿À¿¡¼­ Åõ¸íÇÏ°í ¼±ºÒÀûÀÎ °¡°Ý Ã¥Á¤À» ¿ä±¸Çϸ鼭 Áø·á´ç ¸ðµ¨¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â Áø·á ÆÐŰÁö °¡°ÝÀ» Á¦°øÇϰí, Áø·áºñ¸¦ ¿Â¶óÀÎÀ¸·Î ±¤°íÇϰí, Áï½Ã û±¸ ¹× ºÐÇÒ ÁöºÒ ¿É¼ÇÀ» Áö¿øÇÏ´Â ÇÉÅ×Å© ÅëÇÕÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ¿Í ÀÇ·áÁø °£ÀÇ Á÷Á¢ °Å·¡¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â Ç÷§ÆûÀº Per Encounter ÀÇ·á û±¸ÀÇ È®À强°ú Åõ¸í¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

¿Ö Á¤Ã¥ °³Çõ, ÁöºÒÀÚ Àμ¾Æ¼ºê, Àü¹® ¼­ºñ½º°¡ ±¸Á¶Àû ÁøÈ­¸¦ ÃËÁøÇϴ°¡?

¼¼°è¿¡¼­ ÀÇ·á ÁöºÒ±â°üµéÀº Áø·á °Ç´ç ÁöºÒ±Ý°ú ǰÁú Àμ¾Æ¼ºê, º»Àκδã±Ý Á¶Á¤ ¶Ç´Â ¼º°ú ±â¹Ý º¸³Ê½º¸¦ °áÇÕÇÑ È¥ÇÕÇü ÁöºÒ ¸ðµ¨À» ½ÃµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô °á°ú¿¡ ´ëÇÑ Ã¥ÀÓÀ» ºÎ¿©ÇÏ´Â µ¿½Ã¿¡ û±¸ÀÇ ¼¼¹ÐÇÔÀ» À¯ÁöÇϸ鼭 ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ¼º°ú¿¡ ´ëÇÑ Ã¥ÀÓÀ» À¯µµÇÏ´Â ¹æ½ÄÀÔ´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¸ÞµðÄɾî¿Í ¹Î°£ º¸Çè»çµéÀÌ CPT ÄÚµå °³Á¤ ¹× °¡Ä¡ ±â¹Ý ¸ðµðÆÄÀ̾î¿Í 1ȸ´ç Áø·áºñ¸¦ ÀÏÄ¡½ÃŰ·Á´Â ¿òÁ÷ÀÓÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ÀÇ·á ½Ã½ºÅÛÀÌ ±¹¿µÈ­µÈ ±¹°¡¿¡¼­´Â ¿Ü·¡ Áø·á ´ë±â, Àü¹®ÀÇ Áø·á, ¿ø°ÝÀÇ·áÀÇ ¿À¹öÇ÷ο츦 °ü¸®Çϱâ À§ÇØ ¹æ¹®´ç ¸ðµ¨À» »ç¿ëÇϰí ÀÖ½À´Ï´Ù.

ÇǺΰú Àü¹®ÀÇ, ¾È°ú Àü¹®ÀÇ, ÅëÁõ°ü¸® Àü¹®ÀÇ, Á¤½Å°ú Àü¹®ÀÇ¿Í °°Àº Àü¹® ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ¿¹Ãø °¡´ÉÇÑ Áø·á ±â°£°ú Ç¥ÁØÈ­µÈ Áø·á °æ·Î¸¦ ÅëÇØ Áø·áº° ÇÁ·¹ÀÓ¿öÅ©¿¡ µû¶ó È¿À²ÀûÀ¸·Î ¿î¿µµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌµé ºÐ¾ß´Â ¼­ºñ½ºº°·Î û±¸µÇ´Â Áø´Ü ¹× ¿µ»ó Áø´Ü º¸Á¶¸¦ Ȱ¿ëÇÏ¿© Áõ°Å¿¡ ±â¹ÝÇÑ Áø·á Á¦°ø¿¡¼­ ¹þ¾î³ªÁö ¾Ê°í ¸ÅÃâ ±âȸ¸¦ ±Ø´ëÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¸ðµ¨ÀÇ À¯¿¬¼ºÀº ½ÅÈï ÀÇ·á ±â¼ú ½ºÅ¸Æ®¾÷, ÄÁ½Ã¾îÁö Ŭ¸®´Ð, ±¹°æ °£ ÀÇ·á °ü±¤ »ç¾÷ÀÚ¿¡°Ô ƯÈ÷ ¸Å·ÂÀûÀÔ´Ï´Ù.

Per Encounter ÀÇ·á ½ÃÀåÀÇ Áö¼ÓÀûÀÎ °ü·Ã¼º°ú ¼¼°è ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

Per Encounter ÀÇ·á ½ÃÀåÀÇ ¼ºÀåÀº °Å·¡ ¸íÈ®¼º¿¡ ´ëÇÑ ¼ö¿ä, ¿ø°ÝÀÇ·áÀÇ ºÎ»ó, ÁÖ¿ä ÀÇ·á ºÎ¹®¿¡¼­ ¼ö¼ö·á ¼­ºñ½º °æÁ¦¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÀÇÁ¸ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ȯÀÚ È帧À» Á¦¾îÇϰí, û±¸ Áֱ⸦ ÃÖÀûÈ­Çϰí, ȯÀÚ ¼öÀÇ º¯µ¿¿¡ °ü°è¾øÀÌ ¾ÈÁ¤ÀûÀÎ ¼öÀÔÀ» À¯ÁöÇÏ·Á´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô ¿î¿µ °£¼ÒÈ­¸¦ Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù.

¹°¸®Àû Áø·á¿Í °¡»ó Áø·á°¡ °áÇÕµÈ ÇÏÀ̺긮µå Áø·á Á¦°ø ¸ðµ¨ÀÌ È®»êµÊ¿¡ µû¶ó ¼¼¼Ç´ç °ú±Ý ¹æ½ÄÀº È®Àå °¡´ÉÇÏ°í ¸ðµâÈ­µÈ ¸ÅÃâ âÃâ ÇÁ·¹ÀÓ¿öÅ©¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ¸ðµ¨Àº ƯÈ÷ ÁöºÒÀÚ ½Ã½ºÅÛÀÌ ¹ß´ÞÇÏÁö ¾Ê¾Ò°Å³ª ȯÀÚ°¡ ÀÚºñ¸¦ ºÎ´ãÇÏ´Â ½ÅÈï ½ÃÀå¿¡¼­ ÀÇ·á ¼­ºñ½º ¸ÅÃâ âÃâÀÇ ÇÙ½ÉÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. µðÁöÅРû±¸ Åø, ȯÀÚ Á᫐ °¡°Ý Àü·«, ½Ã¼ú ±â¹Ý Æ÷ÀåÀÌ Àü ¼¼°è¿¡¼­ ¹ßÀüÇϰí ÀÖ´Â °¡¿îµ¥, ƯÈ÷ °í󸮷® ¼ÒºñÀÚ ÀÇ·á ¼­ºñ½º¿¡¼­ ´ë¸é û±¸ ¸ðµ¨Àº ¾ÕÀ¸·Îµµ °ü·Ã¼ºÀÌ À¯ÁöµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¼Ò¸ðǰ, µð¹ÙÀ̽º, ¼ÒÇÁÆ®¿þ¾î, ¼­ºñ½º, ±âŸ Á¦Ç° À¯Çü);À¯Åë ä³Î(Á÷Á¢ ÀÔÂû, ¼Ò¸Å ÆÇ¸Å, ¿Â¶óÀÎ ÆÇ¸Å);¾ÖÇø®ÄÉÀ̼Ç(¼øÈ¯±â°ú, Á¤Çü¿Ü°ú, »êºÎÀΰú, ¾È°ú, ¼ÒÈ­±â°ú, ±âŸ ¾ÖÇø®ÄÉÀ̼Ç)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 44»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <gt; Áß±¹ <gt; ¸ß½ÃÄÚ <gt; ij³ª´Ù <gt;EU <gt; ÀϺ» <gt; Àεµ <gt; ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤À» Àû¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Per Encounter Medical Market to Reach US$303.2 Billion by 2030

The global market for Per Encounter Medical estimated at US$130.7 Billion in the year 2024, is expected to reach US$303.2 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$91.6 Billion by the end of the analysis period. Growth in the Devices segment is estimated at 17.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$35.6 Billion While China is Forecast to Grow at 19.8% CAGR

The Per Encounter Medical market in the U.S. is estimated at US$35.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$64.7 Billion by the year 2030 trailing a CAGR of 19.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 13.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.9% CAGR.

Global Per Encounter Medical Market - Key Trends & Drivers Summarized

Why Is the Per Encounter Medical Model Gaining Attention in Today’s Healthcare Economics?

The per encounter medical model-where healthcare providers are reimbursed based on individual patient visits or treatment events-continues to play a central role in global health systems, particularly in fee-for-service environments. Despite rising advocacy for value-based care, many outpatient clinics, urgent care centers, dental practices, diagnostic laboratories, and specialist consultations still rely heavily on per-visit billing structures. This model provides immediate financial clarity and operational simplicity, allowing providers to optimize throughput, resource allocation, and cash flow.

One of the key reasons behind the model’s resilience is its applicability in fragmented healthcare systems where payer coordination, electronic health record (EHR) interoperability, and outcome tracking remain limited. The model is particularly prevalent in low- and middle-income countries, as well as in private and semi-private health sectors of advanced economies, where bundled payments or capitation systems are still in developmental stages. For providers handling episodic, low-acuity care-such as minor procedures, consultations, or diagnostics-per encounter reimbursement remains economically viable and administratively efficient.

How Are Digital Health Platforms, Patient Preferences, and Transparency Demands Impacting Per Encounter Billing?

Digital transformation is redefining how per encounter models operate in practice. Telemedicine consultations, remote diagnostic tests, and mobile health checkups are increasingly being billed on a per-session basis, creating a new digital layer to the traditional encounter-based framework. These services offer patients flexibility and convenience while enabling providers to tap into broader markets without the overhead of brick-and-mortar expansion. In markets where pay-per-visit telehealth services are reimbursable, this model is accelerating care delivery in underserved and rural regions.

Patients themselves are influencing the per encounter model by seeking transparent, up-front pricing-especially in elective procedures, preventive screenings, and self-pay scenarios. This shift is driving healthcare providers to offer packaged pricing for visits, advertise consultation fees online, and embrace fintech integrations that support instant billing and installment options. Platforms that enable direct patient-provider transactions are enhancing the scalability and transparency of per encounter medical billing.

Why Are Policy Reforms, Payer Incentives, and Specialty Services Driving Structural Evolution?

Globally, healthcare payers are experimenting with blended payment models that merge per encounter rates with quality incentives, co-pay adjustments, or performance-based bonuses. This approach maintains the granularity of fee-for-service billing while nudging providers toward outcome accountability. In the U.S., Medicare and private insurers are increasingly aligning per encounter payments with CPT code revisions and value-based modifiers. Meanwhile, countries with nationalized healthcare systems are using per visit models to manage outpatient care queues, specialist consultations, and telehealth overflow.

Specialty care providers-including dermatologists, ophthalmologists, pain management specialists, and mental health practitioners-often operate efficiently within per encounter frameworks due to predictable visit durations and standardized care pathways. These fields are also leveraging diagnostic and imaging adjuncts billed per service, maximizing revenue opportunities without deviating from evidence-based care delivery. The model’s flexibility makes it particularly attractive for emerging healthtech startups, concierge clinics, and cross-border medical tourism operators.

What’s Driving the Continued Relevance and Global Growth of the Per Encounter Medical Market?

The growth in the per encounter medical market is driven by several factors including the demand for transactional clarity, the rise of telemedicine, and ongoing reliance on fee-for-service economics in key healthcare segments. A primary growth driver is the operational simplicity it offers to providers who seek to control patient flow, optimize billing cycles, and maintain consistent income across fluctuating volumes.

As hybrid care delivery models gain traction-blending physical and virtual encounters-per session billing provides a scalable and modular revenue framework. In emerging markets, the model remains a cornerstone of healthcare monetization, especially where payer systems are underdeveloped or patients pay out-of-pocket. With digital billing tools, patient-centric pricing strategies, and procedure-based packaging evolving globally, the per encounter model is expected to retain relevance-particularly in high-throughput, consumer-facing healthcare services.

SCOPE OF STUDY:

The report analyzes the Per Encounter Medical market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Consumables, Devices, Software, Services, Other Product Types); Distribution Channel (Direct Tender, Retail Sales, Online Sales); Application (Cardiology, Orthopedics, Obstetrics / Gynecology, Ophthalmology, Gastroenterology, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â